期刊
JOURNAL OF CLINICAL MEDICINE
卷 9, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/jcm9082472
关键词
glycoproteins; early rheumatoid arthritis; cardiovascular risk; atherosclerosis; inflammation; H-NMR
资金
- European Union FEDER funds
- Fondo de Investigacion Sanitaria (ISCIII, Spain) [PI16/00113]
- Plan de Ciencia, Tecnologia e Innovacion FICYT 2018-2020 del Principado de Asturias [IDI/2018/000152]
- Juan de la Cierva program (Ministry of Science, Innovation and Universities, Spain) [IJCI-2017-32070]
- Sara Borrell program (ISCIII) [CD19/00120]
- ISPA Intramural Program (ISPA Emergentes JRC
- from ISPA)
This study aimed at evaluating the clinical relevance of glycoprotein profiles during the earliest phases of rheumatoid arthritis (RA) as biomarkers of cardiovascular (CV) risk and treatment response. Then, GlycA and GlycB serum levels were measured using 1H-nuclear magnetic resonance in 82 early RA patients, 14 clinically-suspect arthralgia (CSA), and 28 controls. Serum glycosyltransferase activity was assessed by a colorimetric assay. Subclinical CV disease was assessed by Doppler-ultrasound. We found that GlycA and GlycB serum levels were increased in RA (bothp< 0.001), but not in CSA, independently of cardiometabolic risk factors. Increased serum glycosyltransferase activity paralleled GlycA (r = 0.405,p< 0.001) and GlycB levels (r = 0.327,p= 0.005) in RA. GlycA, but not GlycB, was associated with atherosclerosis occurrence (p= 0.012) and severity (p= 0.001). Adding GlycA to the mSCORE improved the identification of patients with atherosclerosis over mSCORE alone, increasing sensitivity (29.7 vs. 68.0%) and accuracy (55.8 vs. 76.6%) and allowing reclassification into more appropriate risk categories. GlycA-reclassification identified patients with impaired lipoprotein metabolism. Finally, baseline GlycA levels predicted poor clinical response upon anti-rheumatic treatment at 6 and 12 months in univariate and multivariate analysis. In sum, increased GlycA levels during the earliest stage of RA can be considered a powerful biomarker for CV risk stratification and treatment response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据